Hepatitis B surface antigen in late hepatitis B infection

Ceruloplasmin, a reliable marker of fibrosis in chronic hepatitis B virus patients with normal or minimally raised alanine aminotransferase

AIM

To develop a non-invasive model to evaluate significant fibrosis and cirrhosis by investigating the association between serum ceruloplasmin (CP) levels and liver fibrosis in chronic hepatitis B (CHB) patients with normal or minimally raised alanine aminotransferase (ALT).

METHODS

Serum samples and liver biopsy were obtained from 193 CHB patients with minimally raised or normal ALT who were randomly divided into a training group (n = 97) and a validation group (n = 96). Liver histology was evaluated by the METAVIR scoring system. Receiver operator characteristic curves were applied to the diagnostic value of CP for measuring liver fibrosis in CHB patients. Spearman rank correlation analyzed the relationship between CP and liver fibrosis. A non-invasive model was set up through multivariate logistic regression analysis.

RESULTS

Serum CP levels individualized various fibrosis stages via area under the curve (AUC) values. Multivariate analysis revealed that CP levels were significantly related to liver cirrhosis. Combining CP with serum GGT levels, a CG model was set up to predict significant fibrosis and liver cirrhosis in CHB patients with normal or minimally raised ALT. The AUC, sensitivity, specificity, positive predictive value, and negative predictive value were 0.84, 83.1%, 78.6%, 39.6%, and 96.5% to predict liver cirrhosis, and 0.789, 80.26%, 68.38%, 62.25%, and 84.21% to predict significant fibrosis. This model expressed a higher AUC than FIB-4 (age, ALT, aspartate aminotransferase, platelets) and GP (globulin, platelets) models to predict significant fibrosis (P = 0.019 and 0.022 respectively) and revealed a dramatically greater AUC than FIB-4 (P = 0.033) to predict liver cirrhosis.

CONCLUSION

The present study showed that CP was independently and negatively associated with liver fibrosis. Furthermore, we developed a novel promising model (CG), based on routine serum markers, for predicting liver fibrosis in CHB patients with normal or minimally raised ALT.

Association between expression level of mesencephalic astrocyte-derived neurotrophic factor protein and disease progression in patients with chronic hepatitis B virus infection

AIM: To investigate the expression level of endoplasmic reticulum stress related mesencephalic astrocyte-derived neurotrophic factor (MANF) protein and assess its clinical significance in patients with chronic hepatitis B virus (HBV) infection.

METHODS: The expression levels of MANF protein in peripheral blood plasma was measured by ELISA in asymptomatic hepatitis B virus surface antigen (HBsAg) carriers (ASC), chronic hepatitis B (CHB), compensatory liver cirrhosis (CLC) and decompensated liver cirrhosis (DLC) patients after chronic HBV infection and normal healthy controls (HC). The relationship between MANF protein expression and different stages of chronic HBV infection was analyzed.

RESULTS: The expression levels of MANF protein among the HC, ASC, CHB, CLC, and DLC groups had a statistically significant difference (F = 7.391, P = 0.00). Further data analysis showed that the expression levels of MANF protein in the CLC and DLC groups had a statistically significant difference compared with the HC, ASC and CHB groups, but there was no significant difference between the HC, ASC and CHB groups. The expression levels of MANF protein had a statistically significant difference in the three groups of patients stratified by HBsAg level (< 1500 IU/mL, 1500-20000 IU/mL and > 20000 IU/mL) (F = 9.420, P = 0.000). The difference in MANF protein expression levels was statistically significant between patients with different levels of aspartate aminotransferase and total bilirubin, but there was no statistical difference between patients with different levels of alanine aminotransferase, HBV DNA, or between hepatitis B e antigen (HBeAg) positive group and HBeAg-negative group.

CONCLUSION: The expression levels of MANF protein are negatively associated with the disease progression in patients with chronic HBV infection.

HBeAg-negative chronic hepatitis patients should be monitored more strictly: a cross-sectional retrospective study on antiviral treatment-naïve patients

AIM

To investigate the prevalence and characteristics of hepatitis B e antigen (HBeAg) negative/treatment naïve subjects with low hepatitis B virus (HBV) DNA levels (<10(4)  copies/ml) and low alanine aminotransferase (ALT) levels (<2 × upper limit of normal) in patients with HBV-related hepatocellular carcinoma (HCC).

METHODS

A total of 226 treatment naïve patients diagnosed with HBV-related HCC, divided into five Barcelona Clinic Liver Cancer (BCLC) stages, were enrolled and retrospectively analyzed. Virological parameters including hepatitis B surface antigen (HBsAg), HBeAg, HBV DNA levels, and laboratory parameters including ALT and aspartame aminotransferase were accessed at the time of HCC was diagnosed. Comparison between HBeAg positive patients and HBeAg negative patients was performed using a χ(2) test.

RESULTS

While laboratory parameters correlated with BCLC stages, virological parameters did not. HBeAg negative patients were more prevalent than HBeAg positive patients (160, 70.8% vs. 66, 29.2%). HBsAg and HBV DNA levels in HBeAg negative patients were significantly lower than that in HBeAg positive patients (all P < 0.001). Of the 160 HBeAg negative patients, 74 (46.25%) had low HBsAg, 76 (47.5%) had low DNA levels, and 35 (21.9%) patients had low DNA and normal ALT levels.

CONCLUSIONS

In treatment naïve patients with HBV-related HCC, the majority (70.8%) were HBeAg negative patients. More than one fifth of HBeAg negative patients had low HBV DNA levels and normal ALT levels, indicating more strict monitoring for HBeAg negative patients is needed.